Gastroesophageal Junction Adenocarcinoma Clinical Trials in Madison, Wisconsin
7 recruitingMadison, Wisconsin
Showing 1–7 of 7 trials
Recruiting
Phase 2Phase 3
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
Clinical Stage III Gastric Cancer AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IV Gastric Cancer AJCC v8+13 more
National Cancer Institute (NCI)224 enrolled370 locationsNCT06203600
Recruiting
Phase 3
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
Gastroesophageal Junction AdenocarcinomaHER2-positive Gastric Cancer
AstraZeneca840 enrolled286 locationsNCT06764875
Recruiting
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Head and Neck CarcinomaMalignant Solid NeoplasmSarcoma+59 more
Alliance for Clinical Trials in Oncology2,000 enrolled745 locationsNCT05334069
Recruiting
Phase 2Phase 3
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
Gastroesophageal Junction AdenocarcinomaPeritoneal CarcinomatosisGastric Adenocarcinoma
ECOG-ACRIN Cancer Research Group148 enrolled10 locationsNCT07001748
Recruiting
Phase 2
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
Metastatic Breast CancerBreast NeoplasmsGastroesophageal Junction Adenocarcinoma+7 more
Seagen, a wholly owned subsidiary of Pfizer172 enrolled139 locationsNCT06157892
Recruiting
Phase 1Phase 2
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
Pancreatic Ductal AdenocarcinomaBiliary Tract Cancer (BTC)Gastric or Gastroesophageal Junction Adenocarcinoma
Phanes Therapeutics258 enrolled11 locationsNCT05482893
Recruiting
Phase 2
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Pancreatic CancerGastric CancerLung Cancer+15 more
Apollomics Inc.497 enrolled35 locationsNCT03175224